A treatment for Fabry Disease developed by Amicus Therapeutics has won approval by the FDA. The medication, called Galafold, is the first new treatment made available for the disease in 15 years.
According to Amicus, the medication will carry a price tag of about $315,000 a year, which is less than the $340,000 cost of its main rival in the market, Sanofi’s infused Fabrazyme.
Around 3,000 people in the U.S. are diagnosed with Fabry Disease each year. The genetic condition, which can cause a buildup of fat tissue that threatens organs, can sometimes be fatal.
Read the full Reuters report.